In today's world, Doxefazepam occupies a central place in society. Whether on a personal, professional or cultural level, Doxefazepam has a significant impact on our lives. Throughout history, Doxefazepam has been the subject of study, debate and controversy, which demonstrates its relevance in different areas. In this article, we will explore the role of Doxefazepam and its influence on various aspects of society. From its impact on politics to its involvement in technology, Doxefazepam plays a crucial role in the way we interact with the world around us. Additionally, we will examine how Doxefazepam has evolved over time and how it continues to be a topic of interest today.
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | Hepatic |
Elimination half-life | 3-4 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H14ClFN2O3 |
Molar mass | 348.76 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) |
Doxefazepam (marketed under brand name Doxans) is a benzodiazepine medication It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. It is used therapeutically as a hypnotic. According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.
It was patented in 1972 and came into medical use in 1984.
Section 5.5 of the article Doxefazepam in volume 66 of the World Health Organization's (WHO) and International Agency for Research on Cancer's (IARC) IARC Monographs On The Evaluation Of Carcinogenic Risks To Humans, an article describing the carcinogenic/toxic effects of doxefazepam on humans and experimental animals, states that there is "inadequate evidence in humans for the carcinogenicity of doxefazepam" and limited evidence in experimental for the carcinogenicity of doxefazepam," and concluded that the overall evaluation of the substance's carcinogenicity to humans is "not classifiable."